Recurrent Transformed Non-Hodgkin Lymphoma Clinical Trials

11 clinical trials for Recurrent Transformed Non-Hodgkin Lymphoma across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma — RECRUITING · PHASE1
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome — RECRUITING · PHASE2
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma — RECRUITING · PHASE1
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy — RECRUITING · PHASE2
Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment — ACTIVE_NOT_RECRUITING · PHASE1
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. — ACTIVE_NOT_RECRUITING · PHASE1
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma — OTHER · PHASE1
huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia — TERMINATED · PHASE1
Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma — COMPLETED · PHASE1
Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL — TERMINATED · PHASE2

Refine this search